Literature DB >> 6102600

Receptor interactions of imidazolines. IV. Structural requirements for alpha adrenergic receptor occupation and receptor activation by clonidine and a series of structural analogs in rat aorta.

R R Ruffolo, J E Waddell, E L Yaden.   

Abstract

Clonidine and a series of nine halogen and alkyl-substituted structural analogs were evaluated for alpha adrenergic receptor agonist activity in rat aorta. Phenylephrine was included for comparison. All the imidazolines were partial agonists with respect to phenylephrine due to the fact that they only weakly activated the receptor. Whereas phenylephrine requires approximately 0.2% receptor occupancy to produce a response 20% of maximum, the imidazolines required from 25 to 100% receptor occupancy to produce the same response. Although clonidine and its structural analogs are from 125 to 500 times weaker activators of the alpha adrenergic receptor than phenylephrine, they have from 2 to 60 times higher affinity for the receptor than phenylephrine. The results support our previous conclusions that a dichotomy exists between the factors that direct receptor occupation and receptor activation since the structural requirements for each of these parameters differ.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6102600

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  13 in total

1.  Centrally acting imidazolines stimulate vascular alpha 1A-adrenergic receptors in Rat-Tail Artery.

Authors:  Wentsworth B Kennedy; Louis Crane; Ramon R Gonzalez; Oommen K George; Lincoln P Edwards
Journal:  Cell Mol Neurobiol       Date:  2006-08-02       Impact factor: 5.046

2.  Differential response to chloroethylclonidine in blood vessels of normotensive and spontaneously hypertensive rats: role of alpha 1D- and alpha 1A-adrenoceptors in contraction.

Authors:  M Ibarra; J P Pardo; J J Lopez-Guerrero; R Villalobos-Molina
Journal:  Br J Pharmacol       Date:  2000-02       Impact factor: 8.739

3.  Proceedings of the Fiftieth Anniversary Meeting of the British Pharmacological Society, University of Oxford, 16-18 September 1981. Abstracts.

Authors: 
Journal:  Br J Pharmacol       Date:  1981-12       Impact factor: 8.739

4.  The relative contribution of affinity and efficacy to agonist activity: organ selectivity of noradrenaline and oxymetazoline with reference to the classification of drug receptors.

Authors:  T P Kenakin
Journal:  Br J Pharmacol       Date:  1984-01       Impact factor: 8.739

5.  The effect of microelectrophoretically applied clonidine on single cerebral cortical neurones in the rat. Evidence for interaction with alpha 1-adrenoceptors.

Authors:  C M Bradshaw; M J Stoker; E Szabadi
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1982-09       Impact factor: 3.000

6.  Characterization of postsynaptic alpha-adrenoceptors in rat aortic strips and portal veins.

Authors:  K G Digges; R J Summers
Journal:  Br J Pharmacol       Date:  1983-07       Impact factor: 8.739

7.  Neuronal responses to noradrenaline in the cerebral cortex: evidence against the involvement of alpha 2-adrenoceptors.

Authors:  C M Bradshaw; R D Sheridan; E Szabadi
Journal:  Br J Pharmacol       Date:  1984-06       Impact factor: 8.739

8.  Receptor interactions of imidazolines: alpha-adrenoceptors of rat and rabbit aortae differentiated by relative potencies, affinities and efficacies of imidazoline agonists.

Authors:  R R Ruffolo; J E Waddell
Journal:  Br J Pharmacol       Date:  1982-09       Impact factor: 8.739

9.  Muscarinic receptor occupation and receptor activation in the guinea-pig ileum by some acetamides related to oxotremorine.

Authors:  B Ringdahl
Journal:  Br J Pharmacol       Date:  1984-05       Impact factor: 8.739

10.  Hypotensive and alpha-adrenergic activities of 2-(2,3,6-trichlorophenylimino) and 2-(2,3-dichloro-6-methylphenylimino) imidazolidine, two potent derivatives of clonidine.

Authors:  A de Jonge; P B Timmermans; P A van Zwieten
Journal:  Br J Pharmacol       Date:  1983-03       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.